TY - JOUR T1 - Observations from the OMERACT Drug Safety Summit, May 2008 JF - The Journal of Rheumatology JO - J Rheumatol SP - 2110 LP - 2113 DO - 10.3899/jrheum.090590 VL - 36 IS - 9 AU - LEE S. SIMON AU - C. VIBEKE STRAND AU - MAARTEN BOERS AU - PETER M. BROOKS AU - DAVID HENRY AU - PETER S. TUGWELL Y1 - 2009/09/01 UR - http://www.jrheum.org/content/36/9/2110.abstract N2 - Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions. ER -